FXR agonist 9, identified by its CAS number 2982502-32-7, is a synthetic compound that acts as a selective agonist for the farnesoid X receptor (FXR), a nuclear receptor involved in the regulation of bile acid, lipid, and glucose metabolism. This compound is characterized by its ability to modulate metabolic pathways, making it a subject of interest in the study of metabolic disorders, including non-alcoholic fatty liver disease and diabetes. FXR agonists typically exhibit properties such as enhancing bile acid synthesis and promoting glucose homeostasis. The chemical structure of FXR agonist 9 likely includes specific functional groups that confer its agonistic activity, although detailed structural information is not provided here. Its pharmacological profile may include effects on lipid profiles and anti-inflammatory properties, contributing to its potential therapeutic applications. As with many research compounds, the safety, efficacy, and mechanism of action of FXR agonist 9 would require further investigation through preclinical and clinical studies.

FXR agonist 9

2982502-32-7: FXR agonist 9, identified by its CAS number 2982502-32-7, is a synthetic compound that acts as a selective agonist for the farnesoid X receptor (FXR), a nuclear receptor involved in the regulation of bile acid, lipid, and glucose metabolism. This compound is characterized by its ability to modulate metabolic pathways, making it a subject of interest in the study of metabolic disorders, including non-alcoholic fatty liver disease and diabetes. FXR agonists typically exhibit properties such as enhancing bile acid synthesis and promoting glucose homeostasis. The chemical structure of FXR agonist 9 likely includes specific functional groups that confer its agonistic activity, although detailed structural information is not provided here. Its pharmacological profile may include effects on lipid profiles and anti-inflammatory properties, contributing to its potential therapeutic applications. As with many research compounds, the safety, efficacy, and mechanism of action of FXR agonist 9 would require further investigation through preclinical and clinical studies.

FXR agonist9 (compound 26) is a selective, orally active partial agonist of FXR with an EC50 of 0.09 µM (maximum efficacy of 75.13%). It ameliorates the pathological features of fatty liver disease in mice induced by HFD and CCl4-related metabolic dysfunction.

CAS 2982502-32-7

FXR agonist 9

FXR agonist 9

Ref: TM-T201586